These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22929575)

  • 1. [A procalcitonin-guided algorithm for pneumonia may reduce antibiotic use and treatment duration].
    Berg P; Lindhardt BØ
    Ugeskr Laeger; 2012 Aug; 174(35):1986-9. PubMed ID: 22929575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in community-acquired pneumonia.
    Krüger S; Welte T
    Expert Rev Respir Med; 2012 Apr; 6(2):203-14. PubMed ID: 22455492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to reduce antibiotic consumption for community-acquired pneumonia?
    Montassier E; Goffinet N; Potel G; Batard E
    Med Mal Infect; 2013 Feb; 43(2):52-9. PubMed ID: 23433607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia.
    Esposito S; Tagliabue C; Picciolli I; Semino M; Sabatini C; Consolo S; Bosis S; Pinzani R; Principi N
    Respir Med; 2011 Dec; 105(12):1939-45. PubMed ID: 21959024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.
    Long W; Deng X; Zhang Y; Lu G; Xie J; Tang J
    Respirology; 2011 Jul; 16(5):819-24. PubMed ID: 21507143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
    Christ-Crain M; Stolz D; Bingisser R; Müller C; Miedinger D; Huber PR; Zimmerli W; Harbarth S; Tamm M; Müller B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):84-93. PubMed ID: 16603606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empiric antimicrobial therapy of community-acquired pneumonia: clinical diagnosis versus procalcitonin levels.
    Cunha BA
    Scand J Infect Dis; 2009; 41(10):782-4. PubMed ID: 19681019
    [No Abstract]   [Full Text] [Related]  

  • 8. A CAP on antibiotic duration.
    Wunderink RG
    Am J Respir Crit Care Med; 2006 Jul; 174(1):3-5. PubMed ID: 16793998
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum procalcitonin level: clinical significance.
    Aggarwal D; Mohapatra PR; Aggarwal P
    Eur Respir J; 2011 Mar; 37(3):723; author reply 723. PubMed ID: 21357930
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
    Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B
    Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
    Lindstrom ST; Wong EK
    Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Utility of serum procalcitonin as a diagnostic guide in children with community-acquired pneumonia].
    García-Zarza Martínez E; Ramos Amador JT; Rubio Gribble B; Corrales del Río E; Zeballos Sarrato G; Herrera Montes J
    An Pediatr (Barc); 2004 Mar; 60(3):279-81. PubMed ID: 14987523
    [No Abstract]   [Full Text] [Related]  

  • 13. Can procalcitonin testing reduce antibiotic prescribing for respiratory infections?
    Bignardi GE; Dhar R; Heycock R; Bansal S; Majmudar N
    Age Ageing; 2006 Nov; 35(6):625-6. PubMed ID: 16822805
    [No Abstract]   [Full Text] [Related]  

  • 14. Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a clinical observation in geriatric patients.
    Heppner HJ; Bertsch T; Alber B; Esslinger AS; Dragonas C; Bauer JM; Sieber CC
    Gerontology; 2010; 56(4):385-9. PubMed ID: 19940454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum procalcitonin levels and empirical antibiotic treatment of patients with community-acquired febrile syndromes.
    Villanueva JL; Cervin RJ
    Clin Infect Dis; 2003 Mar; 36(6):822; author reply 826-7. PubMed ID: 12627370
    [No Abstract]   [Full Text] [Related]  

  • 16. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?
    Harrison M; Collins CD
    Infect Control Hosp Epidemiol; 2015 Mar; 36(3):265-72. PubMed ID: 25695167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
    Torres A; Ramirez P; Montull B; Menéndez R
    Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procalcitonin-based guidelines and lower respiratory tract infections.
    Stijnis C; van Nieuwkoop C; van Dissel JT
    JAMA; 2010 Feb; 303(5):418-9; author reply 419-20. PubMed ID: 20124533
    [No Abstract]   [Full Text] [Related]  

  • 19. Procalcitonin and severity of community-acquired pneumonia.
    Okimoto N; Hayashi Y; Ishiga M; Nanba F; Kishimoto M; Yagi S; Kurihara T; Asaoka N; Tamada S
    J Infect Chemother; 2009 Dec; 15(6):426-7. PubMed ID: 20012738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.
    Berg P; Lindhardt BØ
    Dan Med J; 2012 Mar; 59(3):A4357. PubMed ID: 22381083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.